FINDINGS:
Pulmonary parenchyma: Clear lungs without focal mass. No suspicious nodules identified.
Mediastinum: Cardiomediastinal contours within normal limits. no mediastinal mass.
Pleura/Pleural spaces: No pleural effusion or pleural thickening. pleural calcifications.
Great vessels/Aorta: No thoracic aortic aneurysm or dissection. mild aortic atherosclerosis.
Liver: No focal hepatic lesions. Normal attenuation.
Spleen: Normal in size and attenuation. No focal splenic lesion.
Pancreas: Normal pancreatic contour and enhancement. No focal mass.
Adrenal glands: Adrenal glands are normal without nodules.
Kidneys: No hydronephrosis. No enhancing renal mass. angiomyolipoma (macroscopic fat).
GI tract/Bowel: No obstructive process. No focal bowel wall mass identified.
Mesentery/Omentum: No ascites. No omental caking. no peritoneal nodularity.
Mesenteric vessels (SMA/SMV): SMA/SMV are patent without thrombosis.
Urinary bladder: Unremarkable. no focal bladder wall thickening.
Reproductive organs: 79 mm smooth mass within the prostate gland, peripheral zone. No adnexal mass. Uterus/prostate within expected size for age.
Lymph nodes: Enlarged celiac lymph node, short axis 18 mm. Enlarged obturator lymph node, short axis 10 mm. No pathologically enlarged lymph nodes by size criteria.
Bones/Osseous structures: No aggressive osseous lesion. No acute fracture. no destructive osseous lesion.

IMPRESSION:
- Prostate primary malignancy at prostate gland, peripheral zone measuring approximately 79 mm.
- Findings concerning for nodal involvement.
- No definite distant metastases identified.
- RECIST 1.1 Summary:
- Target lesions (n=2; ≤2 per organ rule applied).
  • T1: Primary — 79 mm (longest diameter) at baseline.
  • T2: Lymph node — 18 mm (short axis) at baseline.
- SLD baseline: 97 mm.
- New lesions: absent (unequivocal).
- - RECIST 1.1 overall response category: Baseline (no category).
